Clinical Trial Update: A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10 [Phase 2]

View source ↗

Summary

A Phase II clinical study protocol evaluating HIPEC combined with NIPS and tislelizumab as conversion therapy for gastric cancer with peritoneal metastasis; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer with Peritoneal Metastases

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Hebei Medical University | Conditions: Gastric Cancer Peritoneal Metastases | Phase 2 | Status: NOT_YET_RECRUITING